






Information regarding the Limited Exclusive License Agreement for 2018 
 
The University of Saskatchewan (VIDO-InterVac) and Kenya Agricultural and Livestock 
Research Organisation (KALRO) were the recipients of grant funds awarded by the 
International Development Research Centre of the Government of Canada that funded the 
research project to develop a vaccine for Contagious Bovines Pleuropneumonia (CBPP) in 
cattle. The International Livestock Research Institute (ILRI) participated in the project via a 
subcontract from KALRO (then KARI) to ILRI in 2011 and contributed its knowhow and 
research on the expression of candidate vaccine Mycoplasma proteins and the antigens to 
use and bioinformatic analysis which resulted in the identification of a number of 
Mycoplasma mycoides antigens, resulting in the identification of candidate vaccine and 
diagnostic antigen targets.  
 
The vaccine is patented1 and licensed by the Licensors (VIDO-InterVac, KALRO and ILRI) to 
the Kenya Veterinary Vaccines Production Institute (KEVEVAPI) under a Limited Exclusive 
License Agreement. Under the Agreement, VIDO-Intervac is the patenting and 
commercialization lead and KEVEVAPI is granted a limited exclusive right to manufacture, 
use, lease and sell the vaccine in Burundi, Democratic Republic of Congo, Ethiopia, Kenya, 
Rwanda, Sudan, Tanzania, Uganda, Malawi, Mozambique, Namibia, Swaziland, Zambia and 
Zimbabwe.  
 
The rationale for applying for the patent is to ensure continued availability of the vaccine to 
poor farmers, prevent mis-appropriation by third parties for profit making and to ensure 
the delivery of improved products and technologies in developing countries. 
 
In accordance with the CGIAR Intellectual Assets Principles, the Licensors retain the right to 
use and make the vaccine for non-commercial research conducted by public sector 
organizations, educational and/or scholarly research uses undertaken or performed by 
employees, students or visitors of the Licensors as well as for food security emergencies 
that pose imminent threat of a significant loss of human life. 
 
                                                          
1 See PCT application with International Application No.:  PCT/CA2016/050864 concerning ‘immunogenic 
compositions and methods for treating/preventing Mycoplasma infection’ accessible at 
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017011919&redirectedID=true  
